Boston Scientific revenue and financials
$42.19Change from previous close: −0.50%Absolute change: −$0.21
In the fiscal year ended December 2025, Boston Scientific reported revenue of $20.07B (+19.87% year over year). Net income was $2.89B, a net margin of 14.4%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +19.87%
- 2025 vs 2024
- Net income growth
- +56.66%
- 2025 vs 2024
- Net margin
- 14.4%
- 2024: 11.0%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 4,534 | 3,435 | 2,503 | 1,526 | 1,870 | 1,508 | 1,836 | 310 | 1,426 | 1,182 |
| Depreciation and amortization | 1,368 | 1,269 | 1,196 | 1,136 | 1,093 | 1,123 | 1,011 | 894 | 844 | 815 |
| Capital expenditure | -876 | -790 | -711 | -588 | -554 | -376 | -461 | -316 | -319 | -376 |
| Investing cash flow | -2,640 | -5,687 | -2,574 | -2,011 | -1,597 | — | — | — | — | — |
| Financing cash flow | -395 | 1,814 | 5.0 | -548 | -95.0 | — | — | — | — | — |
| Dividends paid | — | 0.0 | -28.0 | -55.0 | -55.0 | -28.0 | 0.0 | 0.0 | — | — |
| Share repurchases | — | — | — | 0.0 | 0.0 | -535 | 0.0 | 0.0 | — | 0.0 |
| Debt issued | 1,558 | 2,332 | 0.0 | 3,270 | — | — | — | — | — | — |
| Debt repaid | -2,049 | -529 | -4.0 | -3,435 | — | — | — | — | — | — |
| Effect of exchange rates | 42.0 | -11.0 | -4.0 | -9.0 | -6.0 | — | — | — | — | — |
| Net change in cash | 1,541 | -450 | -70.0 | -1,042 | 173 | — | — | — | — | — |
| Free cash flow | 3,658 | 2,645 | 1,792 | 938 | 1,316 | — | — | — | — | — |
| Levered free cash flow | 3,242 | 1,788 | 1,850 | 1,155 | 2,654 | — | — | — | — | — |